<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1339">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05557409</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-05-AD-304</org_study_id>
    <nct_id>NCT05557409</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation</brief_title>
  <acronym>ADVANCE-2</acronym>
  <official_title>ADVANCE-2: Addressing Dementia Via Agitation-Centered Evaluation 2: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer's Disease Agitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, double-blind, placebo-controlled, randomized study to evaluate&#xD;
      the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation&#xD;
      associated with Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized in a 1:1 ratio for up to 5 weeks to be treated with&#xD;
      AXS-05 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI)</measure>
    <time_frame>Up to 5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Agitation in Patients With Dementia of the Alzheimer's Type</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>AXS-05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Up to 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-05</intervention_name>
    <description>AXS-05 tablets, taken twice daily</description>
    <arm_group_label>AXS-05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, taken twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on&#xD;
             Aging-Alzheimer Association (NIA-AA) criteria.&#xD;
&#xD;
          -  Diagnosis of clinically significant agitation resulting from probable AD according to&#xD;
             the International Psychogeriatric Association (IPA) provisional definition of&#xD;
             agitation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has dementia predominantly of non-Alzheimer's type.&#xD;
&#xD;
          -  Unable to comply with study procedures.&#xD;
&#xD;
          -  Medically inappropriate for study participation in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>212-332-5061</phone>
    <email>ADVANCE-2@axsome.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alzheimers-study.com</url>
    <description>ADVANCE-2 Study Website</description>
  </link>
  <link>
    <url>http://axsome.com/</url>
    <description>Axsome Therapeutics Website</description>
  </link>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>September 23, 2022</study_first_submitted>
  <study_first_submitted_qc>September 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2022</study_first_posted>
  <last_update_submitted>September 23, 2022</last_update_submitted>
  <last_update_submitted_qc>September 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AD agitation</keyword>
  <keyword>AXS-05</keyword>
  <keyword>NMDA receptor antagonist</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>bupropion</keyword>
  <keyword>Axsome</keyword>
  <keyword>ADVANCE-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

